ArticleTranslational cancer research2025
Bulk and single-cell transcriptomics of stomach adenocarcinoma provide prognostic insights via the application of a novel gene signature associated with manganese metabolism.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer (GC), originating from gastric mucosa epithelial cells, is a global health issue, ranking as the fifth most common cancer and fourth in cancer-related deaths. Stomach adenocarcinoma (STAD) accounts for 95% of GC cases. Emerging evidence suggests a link between manganese (Mn) metabolism and GC, but the role of Mn metabolism-related genes (MMRGs) in STAD is unclear. This study aims to bridge this gap of Mn metabolism through the development of a robust prognostic signature derived from The Cancer Genome Atlas (TCGA) data. Methods: We used RNA-sequencing data and clinical information from TCGA to identify STAD subtypes and developed a Mn metabolism scoring model to predict STAD prognosis. Results: An extensive clustering analysis of 115 prognostic MMRGs related to GC facilitated the distinction of two unique subtypes classified as Cluster 1 (C1) and Cluster 2 (C2). The subsequent Kaplan-Meier survival analysis revealed that the C1 subtype had a better survival rate than the C2 subtype. Additionally, a statistically significant difference was observed between the two subtypes in terms of patient age and tumor grade. The box plot examination revealed a marked difference in the immune cell populations, including a diminished presence of B cells, CD4 Conclusions: This study developed a prognostic model for STAD using the expression levels of MMRGs. Our findings provide insights that could inform future targeted therapeutic approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.